E
Adial Pharmaceuticals, Inc.
ADIL
$0.6331
-$0.0417-6.18%
E
Sell
8/23/2023Downgrade
Adial Pharmaceuticals, Inc. (ADIL) was downgraded to E+ from D- on 8/23/2023 due to a decline in the solvency index, volatility index and valuation index.
Adial Pharmaceuticals, Inc. (ADIL) was downgraded to E+ from D- on 8/23/2023 due to a decline in the solvency index, volatility index and valuation index.
D
Sell
8/22/2023Upgraded
Adial Pharmaceuticals, Inc. (ADIL) was upgraded to D- from E+ on 8/22/2023 due to an increase in the volatility index and valuation index.
Adial Pharmaceuticals, Inc. (ADIL) was upgraded to D- from E+ on 8/22/2023 due to an increase in the volatility index and valuation index.
E
Sell
3/14/2023Downgrade
Adial Pharmaceuticals, Inc. (ADIL) was downgraded to E+ from D- on 03/14/2023.
Adial Pharmaceuticals, Inc. (ADIL) was downgraded to E+ from D- on 03/14/2023.
D
Sell
3/2/2023Downgrade
Adial Pharmaceuticals, Inc. (ADIL) was downgraded to D- from D on 3/2/2023 due to a decline in the volatility index.
Adial Pharmaceuticals, Inc. (ADIL) was downgraded to D- from D on 3/2/2023 due to a decline in the volatility index.
D
Sell
2/10/2023Upgraded
Adial Pharmaceuticals, Inc. (ADIL) was upgraded to D from E+ on 2/10/2023 due to an increase in the volatility index and total return index.
Adial Pharmaceuticals, Inc. (ADIL) was upgraded to D from E+ on 2/10/2023 due to an increase in the volatility index and total return index.
E
Sell
2/8/2023Downgrade
Adial Pharmaceuticals, Inc. (ADIL) was downgraded to E+ from D on 2/8/2023 due to a decline in the volatility index.
Adial Pharmaceuticals, Inc. (ADIL) was downgraded to E+ from D on 2/8/2023 due to a decline in the volatility index.
D
Sell
1/24/2023Upgraded
Adial Pharmaceuticals, Inc. (ADIL) was upgraded to D from D- on 1/24/2023 due to an increase in the volatility index.
Adial Pharmaceuticals, Inc. (ADIL) was upgraded to D from D- on 1/24/2023 due to an increase in the volatility index.
D
Sell
1/6/2023Downgrade
Adial Pharmaceuticals, Inc. (ADIL) was downgraded to D- from D on 1/6/2023 due to a decline in the volatility index.
Adial Pharmaceuticals, Inc. (ADIL) was downgraded to D- from D on 1/6/2023 due to a decline in the volatility index.
D
Sell
12/22/2022Upgraded
Adial Pharmaceuticals, Inc. (ADIL) was upgraded to D from D- on 12/22/2022 due to an increase in the volatility index.
Adial Pharmaceuticals, Inc. (ADIL) was upgraded to D from D- on 12/22/2022 due to an increase in the volatility index.
D
Sell
12/7/2022Downgrade
Adial Pharmaceuticals, Inc. (ADIL) was downgraded to D- from D on 12/7/2022 due to a decline in the total return index and volatility index.
Adial Pharmaceuticals, Inc. (ADIL) was downgraded to D- from D on 12/7/2022 due to a decline in the total return index and volatility index.
D
Sell
11/22/2022Upgraded
Adial Pharmaceuticals, Inc. (ADIL) was upgraded to D from D- on 11/22/2022 due to an increase in the growth index. Earnings per share increased from -$0.16 to -$0.1209, EBIT increased 16.78% from -$3.83M to -$3.19M, and operating cash flow increased 3.69% from -$3.53M to -$3.4M.
Adial Pharmaceuticals, Inc. (ADIL) was upgraded to D from D- on 11/22/2022 due to an increase in the growth index. Earnings per share increased from -$0.16 to -$0.1209, EBIT increased 16.78% from -$3.83M to -$3.19M, and operating cash flow increased 3.69% from -$3.53M to -$3.4M.
D
Sell
10/25/2022Downgrade
Adial Pharmaceuticals, Inc. (ADIL) was downgraded to D- from D on 10/25/2022 due to a decline in the volatility index and total return index.
Adial Pharmaceuticals, Inc. (ADIL) was downgraded to D- from D on 10/25/2022 due to a decline in the volatility index and total return index.
D
Sell
10/10/2022Upgraded
Adial Pharmaceuticals, Inc. (ADIL) was upgraded to D from D- on 10/10/2022 due to an increase in the volatility index.
Adial Pharmaceuticals, Inc. (ADIL) was upgraded to D from D- on 10/10/2022 due to an increase in the volatility index.
D
Sell
9/22/2022Downgrade
Adial Pharmaceuticals, Inc. (ADIL) was downgraded to D- from D on 9/22/2022 due to a large decline in the total return index and volatility index.
Adial Pharmaceuticals, Inc. (ADIL) was downgraded to D- from D on 9/22/2022 due to a large decline in the total return index and volatility index.
D
Sell
5/16/2022Upgraded
Adial Pharmaceuticals, Inc. (ADIL) was upgraded to D from E+ on 5/16/2022 due to an increase in the volatility index.
Adial Pharmaceuticals, Inc. (ADIL) was upgraded to D from E+ on 5/16/2022 due to an increase in the volatility index.
E
Sell
5/13/2022Downgrade
Adial Pharmaceuticals, Inc. (ADIL) was downgraded to E+ from D on 5/13/2022 due to a decline in the total return index and volatility index.
Adial Pharmaceuticals, Inc. (ADIL) was downgraded to E+ from D on 5/13/2022 due to a decline in the total return index and volatility index.
D
Sell
5/4/2022Upgraded
Adial Pharmaceuticals, Inc. (ADIL) was upgraded to D from E+ on 5/4/2022 due to an increase in the valuation index.
Adial Pharmaceuticals, Inc. (ADIL) was upgraded to D from E+ on 5/4/2022 due to an increase in the valuation index.
E
Sell
5/1/2022Downgrade
Adial Pharmaceuticals, Inc. (ADIL) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index.
Adial Pharmaceuticals, Inc. (ADIL) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index.
D
Sell
4/21/2022Upgraded
Adial Pharmaceuticals, Inc. (ADIL) was upgraded to D from E+ on 04/21/2022.
Adial Pharmaceuticals, Inc. (ADIL) was upgraded to D from E+ on 04/21/2022.
E
Sell
4/20/2022Downgrade
Adial Pharmaceuticals, Inc. (ADIL) was downgraded to E+ from D on 4/20/2022 due to a large decline in the total return index, volatility index and growth index. Earnings per share declined from -$0.2175 to -$0.2809, and EBIT declined 9.09% from -$4.06M to -$4.43M.
Adial Pharmaceuticals, Inc. (ADIL) was downgraded to E+ from D on 4/20/2022 due to a large decline in the total return index, volatility index and growth index. Earnings per share declined from -$0.2175 to -$0.2809, and EBIT declined 9.09% from -$4.06M to -$4.43M.
D
Sell
11/18/2021Upgraded
Adial Pharmaceuticals, Inc. (ADIL) was upgraded to D from D- on 11/18/2021 due to an increase in the growth index, solvency index and total return index. The quick ratio increased from 2.35 to 3.67, earnings per share increased from -$0.2525 to -$0.22, and EBIT increased 7.73% from -$4.4M to -$4.06M.
Adial Pharmaceuticals, Inc. (ADIL) was upgraded to D from D- on 11/18/2021 due to an increase in the growth index, solvency index and total return index. The quick ratio increased from 2.35 to 3.67, earnings per share increased from -$0.2525 to -$0.22, and EBIT increased 7.73% from -$4.4M to -$4.06M.
D
Sell
11/8/2021Downgrade
Adial Pharmaceuticals, Inc. (ADIL) was downgraded to D- from D on 11/8/2021 due to a large decline in the growth index and valuation index. Operating cash flow declined 12.66% from -$2.84M to -$3.2M.
Adial Pharmaceuticals, Inc. (ADIL) was downgraded to D- from D on 11/8/2021 due to a large decline in the growth index and valuation index. Operating cash flow declined 12.66% from -$2.84M to -$3.2M.
D
Sell
8/14/2020Upgraded
Adial Pharmaceuticals, Inc. (ADIL) was upgraded to D from D- on 8/14/2020 due to a noticeable increase in the growth index, volatility index and solvency index. Operating cash flow increased 46.03% from -$1.83M to -$985.2, earnings per share increased from -$0.2169 to -$0.1604, and EBIT increased 20.93% from -$2.3M to -$1.82M.
Adial Pharmaceuticals, Inc. (ADIL) was upgraded to D from D- on 8/14/2020 due to a noticeable increase in the growth index, volatility index and solvency index. Operating cash flow increased 46.03% from -$1.83M to -$985.2, earnings per share increased from -$0.2169 to -$0.1604, and EBIT increased 20.93% from -$2.3M to -$1.82M.
D
Sell
4/21/2020Downgrade
Adial Pharmaceuticals, Inc. (ADIL) was downgraded to D- from D on 4/21/2020 due to a decline in the volatility index, solvency index and total return index.
Adial Pharmaceuticals, Inc. (ADIL) was downgraded to D- from D on 4/21/2020 due to a decline in the volatility index, solvency index and total return index.
D
Sell
3/23/2020Upgraded
Adial Pharmaceuticals, Inc. (ADIL) was upgraded to D from D- on 3/23/2020 due to an increase in the total return index, volatility index and growth index.
Adial Pharmaceuticals, Inc. (ADIL) was upgraded to D from D- on 3/23/2020 due to an increase in the total return index, volatility index and growth index.
D
Sell
8/19/2019Upgraded
Adial Pharmaceuticals, Inc. (ADIL) was upgraded to D- from E+ on 8/19/2019 due to a noticeable increase in the efficiency index and growth index. Earnings per share increased from -$0.3251 to -$0.21, operating cash flow increased 33.75% from -$1.72M to -$1.14M, and net income increased 20.44% from -$2.68M to -$2.13M.
Adial Pharmaceuticals, Inc. (ADIL) was upgraded to D- from E+ on 8/19/2019 due to a noticeable increase in the efficiency index and growth index. Earnings per share increased from -$0.3251 to -$0.21, operating cash flow increased 33.75% from -$1.72M to -$1.14M, and net income increased 20.44% from -$2.68M to -$2.13M.
E
Sell
7/25/2019Downgrade
Adial Pharmaceuticals, Inc. (ADIL) was downgraded to E+ from D- on 7/25/2019 due to a large decline in the total return index, growth index and efficiency index. Net income declined 111.39% from -$1.27M to -$2.68M, earnings per share declined from -$0.1911 to -$0.3251, and operating cash flow declined 55.91% from -$1.1M to -$1.72M.
Adial Pharmaceuticals, Inc. (ADIL) was downgraded to E+ from D- on 7/25/2019 due to a large decline in the total return index, growth index and efficiency index. Net income declined 111.39% from -$1.27M to -$2.68M, earnings per share declined from -$0.1911 to -$0.3251, and operating cash flow declined 55.91% from -$1.1M to -$1.72M.
D
Sell
4/1/2019Upgraded
Adial Pharmaceuticals, Inc. (ADIL) was upgraded to D- from E on 4/1/2019 due to a noticeable increase in the growth index, total return index and efficiency index. Earnings per share increased from -$1.4767 to -$0.1911, and net income increased 84.51% from -$8.19M to -$1.27M.
Adial Pharmaceuticals, Inc. (ADIL) was upgraded to D- from E on 4/1/2019 due to a noticeable increase in the growth index, total return index and efficiency index. Earnings per share increased from -$1.4767 to -$0.1911, and net income increased 84.51% from -$8.19M to -$1.27M.
E
Sell
1/3/2019Upgraded
Adial Pharmaceuticals, Inc. (ADIL) was upgraded to E from E- on 1/3/2019 due to a substantial increase in the solvency index, volatility index and total return index. The quick ratio increased from 0.1 to 14.92.
Adial Pharmaceuticals, Inc. (ADIL) was upgraded to E from E- on 1/3/2019 due to a substantial increase in the solvency index, volatility index and total return index. The quick ratio increased from 0.1 to 14.92.
E
Sell
10/19/2018None
Adial Pharmaceuticals, Inc. (ADIL) was downgraded to E- from U on 10/19/2018.
Adial Pharmaceuticals, Inc. (ADIL) was downgraded to E- from U on 10/19/2018.
NASDAQ
04/04/2025 3:28PM Eastern
Quotes delayed
